Literature DB >> 12091366

Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis.

Daniel F Wallace1, Palle Pedersen, Jeannette L Dixon, Peter Stephenson, Jeffrey W Searle, Lawrie W Powell, V Nathan Subramaniam.   

Abstract

Hemochromatosis is a common disorder characterized by excess iron absorption and accumulation of iron in tissues. Usually hemochromatosis is inherited in an autosomal recessive pattern and is caused by mutations in the HFE gene. Less common non-HFE-related forms of hemochromatosis have been reported and are caused by mutations in the transferrin receptor 2 gene and in a gene localized to chromosome 1q. Autosomal dominant forms of hemochromatosis have also been described. Recently, 2 mutations in the ferroportin1 gene, which encodes the iron transport protein ferroportin1, have been implicated in families with autosomal dominant hemochromatosis from the Netherlands and Italy. We report the finding of a novel mutation (V162del) in ferroportin1 in an Australian family with autosomal dominant hemochromatosis. We propose that this mutation disrupts the function of the ferroportin1 protein, leading to impaired iron homeostasis and iron overload.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091366     DOI: 10.1182/blood.v100.2.692

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  Hemizygous deletion of COL3A1, COL5A2, and MSTN causes a complex phenotype with aortic dissection: a lesson for and from true haploinsufficiency.

Authors:  Janine Meienberg; Marianne Rohrbach; Stefan Neuenschwander; Katharina Spanaus; Cecilia Giunta; Sira Alonso; Eliane Arnold; Caroline Henggeler; Stephan Regenass; Andrea Patrignani; Silvia Azzarello-Burri; Bernhard Steiner; Anders O H Nygren; Thierry Carrel; Beat Steinmann; Gábor Mátyás
Journal:  Eur J Hum Genet       Date:  2010-07-21       Impact factor: 4.246

2.  Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice.

Authors:  Junwei Gao; Juxing Chen; Ivana De Domenico; David M Koeller; Cary O Harding; Robert E Fleming; Dwight D Koeberl; Caroline A Enns
Journal:  Blood       Date:  2010-02-22       Impact factor: 22.113

3.  Identification of ferroportin disease in the Indian subcontinent.

Authors:  D F Wallace; P Browett; P Wong; H Kua; R Ameratunga; V N Subramaniam
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

4.  Ferroportin disease due to the A77D mutation in Australia.

Authors:  V N Subramaniam; D F Wallace; J L Dixon; L M Fletcher; D H Crawford
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

5.  SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent.

Authors:  James C Barton; Ronald T Acton; Pauline L Lee; Carol West
Journal:  Blood Cells Mol Dis       Date:  2007-05-09       Impact factor: 3.039

6.  The global burden of iron overload.

Authors:  Marnie J Wood; Richard Skoien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2009-07-29       Impact factor: 6.047

Review 7.  The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1).

Authors:  Andrew T McKie; David J Barlow
Journal:  Pflugers Arch       Date:  2003-06-27       Impact factor: 3.657

8.  Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload.

Authors:  Monique G Zaahl; Alison T Merryweather-Clarke; Maritha J Kotze; Schalk van der Merwe; Louise Warnich; Kathryn J H Robson
Journal:  Hum Genet       Date:  2004-08-24       Impact factor: 4.132

Review 9.  Is genetic screening for hemochromatosis worthwhile?

Authors:  Omer T Njajou; Behrooz Z Alizadeh; Cornelia M van Duijn
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

10.  A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient.

Authors:  K E Arden; D F Wallace; J L Dixon; L Summerville; J W Searle; G J Anderson; G A Ramm; L W Powell; V N Subramaniam
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.